EGFR and non-small cell lung carcinoma: LM is a fatal complication in patients with advanced NSCLC and the incidence is increasing, reaching 9% in EGFR-mutant lung cancer patients.[7] The prognosis of patients with LM from NSCLC remains poor.[8] The third-generation EGFR TKI osimertinib, can efficiently penetrate the blood-brain barrier and should be considered in LM with sensitizing EGFR mutations regardless of T790M status.[2,9] However, treatment options remain a challenge for osimertinib resistant NSCLC patients with LM.